These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 31021388)
1. Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. Liu Z; Sun J; Hou J JAMA Oncol; 2019 Jun; 5(6):915. PubMed ID: 31021388 [No Abstract] [Full Text] [Related]
2. Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. Zhang H; Zeng W JAMA Oncol; 2019 Jun; 5(6):914-915. PubMed ID: 31021391 [No Abstract] [Full Text] [Related]
3. Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. Kong Y; Jia J; Yang HI JAMA Oncol; 2019 Jun; 5(6):915-916. PubMed ID: 31021371 [No Abstract] [Full Text] [Related]
4. Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B-in Reply. Choi J; Ko MJ; Lim YS JAMA Oncol; 2019 Jun; 5(6):916-917. PubMed ID: 31021372 [No Abstract] [Full Text] [Related]
5. Tenofovir vs Entecavir for Hepatocellular Carcinoma Prevention in Patients With Chronic Hepatitis B: One of These Things Is Not Like the Other. Flemming JA; Terrault NA JAMA Oncol; 2019 Jan; 5(1):17-18. PubMed ID: 30267036 [No Abstract] [Full Text] [Related]
6. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study. Choi J; Kim HJ; Lee J; Cho S; Ko MJ; Lim YS JAMA Oncol; 2019 Jan; 5(1):30-36. PubMed ID: 30267080 [TBL] [Abstract][Full Text] [Related]
7. Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction. Choi J; Lim YS J Hepatol; 2019 Oct; 71(4):846-847. PubMed ID: 31351769 [No Abstract] [Full Text] [Related]
8. Reply to: "Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction". Kim BK J Hepatol; 2019 Oct; 71(4):847-848. PubMed ID: 31383378 [No Abstract] [Full Text] [Related]
9. Tenofovir versus entecavir in prevention of hepatocellular carcinoma and mortality in patients with chronic hepatitis B. Kamal F; Khan MA; Ahmed A; Nair S Gut; 2020 Nov; 69(11):2054-2056. PubMed ID: 32041745 [No Abstract] [Full Text] [Related]
10. Tenofovir may be superior to entecavir for preventing hepatocellular carcinoma and mortality in individuals chronically infected with HBV: a meta-analysis. Teng YX; Li MJ; Xiang BD; Zhong JH Gut; 2020 Oct; 69(10):1900-1902. PubMed ID: 31843789 [No Abstract] [Full Text] [Related]
11. Comment on - A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea. Yu Y; Zhang J; Zhang B; Gao J J Hepatol; 2020 Jan; 72(1):197-198. PubMed ID: 31733878 [No Abstract] [Full Text] [Related]
12. Is Tenofovir Superior to Entecavir in Reducing the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B? The Controversy Continues. Lampertico P; Papatheodoridis GV Gastroenterology; 2020 Jan; 158(1):42-44. PubMed ID: 31706943 [No Abstract] [Full Text] [Related]
13. Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. Papatheodoridis GV; Sypsa V; Dalekos G; Yurdaydin C; van Boemmel F; Buti M; Goulis J; Calleja JL; Chi H; Manolakopoulos S; Loglio A; Siakavellas S; Gatselis N; Keskın O; Lehretz M; Savvidou S; de la Revilla J; Hansen BE; Kourikou A; Vlachogiannakos I; Galanis K; Idilman R; Colombo M; Esteban R; Janssen HLA; Berg T; Lampertico P J Hepatol; 2018 Jun; 68(6):1129-1136. PubMed ID: 29427727 [TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma. Riveiro-Barciela M; Tabernero D; Calleja JL; Lens S; Manzano ML; Rodríguez FG; Crespo J; Piqueras B; Pascasio JM; Comas C; Gutierrez ML; Aguirre A; Suárez E; García-Samaniego J; Rivero M; Acero D; Fernandez-Bermejo M; Moreno D; Sánchez-Pobre P; de Cuenca B; Moreno-Palomares JJ; Esteban R; Buti M Dig Dis Sci; 2017 Mar; 62(3):784-793. PubMed ID: 28078526 [TBL] [Abstract][Full Text] [Related]
15. Association of tenofovir and entecavir use with prognosis after surgical resection for hepatitis B virus-related hepatocellular carcinoma. Yun B; Ahn SH; Oh J; Yoon JH; Kim BK Eur J Intern Med; 2022 Sep; 103():122-125. PubMed ID: 35835625 [No Abstract] [Full Text] [Related]
16. Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B. Lee HA; Seo YS; Kim SU Gastroenterology; 2020 Jun; 158(8):2310-2311. PubMed ID: 32201178 [No Abstract] [Full Text] [Related]
17. Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred? van Erpecum KJ; Sonneveld MJ Eur J Intern Med; 2021 Jul; 89():27-29. PubMed ID: 34023149 [No Abstract] [Full Text] [Related]
18. Prolonged use of tenofovir and entecavir in hepatitis B virus-related cirrhosis. Goyal SK; Dixit VK; Shukla SK; Ghosh J; Behera M; Tripathi M; Gupta N; Ranjan A; Jain AK Indian J Gastroenterol; 2015 Jul; 34(4):286-91. PubMed ID: 26243587 [TBL] [Abstract][Full Text] [Related]
19. Is Tenofovir Associated with a Lower Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B Compared With Entecavir? Kamal F; Khan MA Gastroenterology; 2020 Jun; 158(8):2311-2312. PubMed ID: 32201182 [No Abstract] [Full Text] [Related]
20. Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine. Lim YS; Han S; Heo NY; Shim JH; Lee HC; Suh DJ Gastroenterology; 2014 Jul; 147(1):152-61. PubMed ID: 24583062 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]